Kiromic BioPharma (KRBP) Announces Management and Board Changes

Kiromic BioPharma, Inc. (NASDAQ: KRBP) a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces changes in management, and in the Company’s Board of Directors. In addition, the Company announces the formation of a Disclosure Committee.

Effective January 27, 2022, Pietro Bersani, Kiromic‘s former Chair of the Audit Committee, was appointed as Interim Chief Executive Officer to succeed Dr. Maurizio Chiriva who departed from his roles as Chief Executive Officer and Chairman of the Company’s Board of Directors as of that date. Effective January 27, 2022, Company Director Michael Nagel was appointed as the Company’s new Chairman of the Board.

“I have been a member of the Kiromic Board of Directors since 2020, and I feel privileged to now lead this Company during this very pivotal year ahead. We have tremendous science, and a very important milestone to reach in the coming months,” stated Interim CEO Bersani. “The Kiromic leadership team is laser focused on realizing our goal of first in-human dosing and initiating clinical trials.”

The Company also announces the formation of a Disclosure Committee, comprised of the Company’s senior leaders, for the purpose of further strengthening the Company’s protocol, process and procedure related to disclosure requirements.

For more information, please see the Company’s recently filed Form 8-K: Inline XBRL Viewer (sec.gov).

You May Also Be Interested In

• Polar Power adds two directors with defense and business experience
• Halozyme adds biotech executive Appelhans to its board
• Kennametal adds two directors with industrial, aerospace backgrounds